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Abstract   16 
Malignancies of the brain are complicated matters. The diagnosis of a brain tumor 17 
monumentally alters the course of life for the patient, their friends, and their family. Gliomas are 18 
the most common type of primary brain tumors in the United States affecting more than 20,000 19 
people annually. Depending on the clinical situation, surgical resection of the mass remains the 20 
primary mode of treatment. Adjuvant therapies with external beam radiation and chemotherapy 21 
are often utilized. In many cases, the most advanced interventional technologies do not cure or 22 
prevent progression of the disease to its final stage - death. The bombardment with multiple 23 
treatment modalities is exhaustive for already ill patients, and even more devastating to patients 24 
and their families when unsuccessful at providing a quality of life that is in accordance with the 25 
patient’s desires. In these cases, it is important to incorporate a discussion of living a higher 26 
quality of life for the limited time the patient has remaining, rather than pursuing a myriad of 27 
experimental treatments. In this manuscript, we present a series of topics necessary to facilitate 28 
this communication between the physician, patient, and their families.  29 
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1. Introduction  35 
The brain is a complex organ composed of multiple cell types, layers, and strata. One of 36 
the primary cell types of brain tissue includes glial cells which serve countless roles in the human 37 
brain. Glial cells can be subdivided into numerous categories, each with a specific function. 38 
Gliomas are tumors of glial cells that affect the human brain and spinal cord. They most 39 
frequently arise from three cell types: astrocytes, oligodendrocytes, and ependymal cells [1]. 40 
Astrocytes are the most abundant glial cell in the brain and act primarily as supporting cells to 41 
the neurons. Oligodendrocytes function in myelin production in order to accelerate propagation 42 
of action potentials between neurons. Astrocytes give rise to astrocytomas; oligodendrocytes 43 
give rise to oligodendrocytomas, and a mix of both cell types gives rise to oligoastrocytomas [2]. 44 
Gliomas are the most frequently diagnosed brain tumor, found in 80% of cases [1].  45 
Astrocytomas are the most prevalent type of gliomas affecting children and adults, alike. These 46 
cancerous growths can be categorized from Grade I to IV according to the World Health 47 
Organization (WHO) grading system. Grade I describes a slow growing or benign tumor with 48 
curative possibilities. Alternatively, Grade IV constitutes the fastest rate of malignant growth 49 
often described as high grade 3.  A glioma is rated on malignant potential according to a multitude 50 
of characteristics namely: size, rate of growth, pathology and molecular genetics [1]. The most 51 
aggressive form of astrocytoma is glioblastoma and is often categorized as Grade IV. Although 52 
there seems to be a pattern in the type and grade of gliomas, in no instance is it implied that a 53 
higher and more dangerous tumor cannot occur in the generally less aggressive categorizations 54 
of glial cancers [4].          55 
The incidence of brain tumors has been increasing and with that, the rate of glioblastoma 56 
diagnosis and mortality. It was observed through a study comparing glioblastomas and other 57 
gliomas that the incidence of both occurs more in Caucasians than in any other ethnic group [1]. 58 
Males were diagnosed more with other types of gliomas than females, with a ratio of 1.38. 59 
Further, the elderly exhibit a higher risk of aggressive gliomas due to genetic modifications [5]. 60 
Astrocytomas peak between the age of 75-84 while oligoastrocytomas and oligodendrogliomas 61 
peak between the ages of 35-44 [5].  It is also noted that more males than females are diagnosed 62 
with a glioblastoma, with a ratio of 1.61.  In another study conducted in Northwestern Greece on 63 
488,435 patients presenting with a brain tumor, it was suggested that gliomas most often affect 64 
the frontal lobe at a frequency of 46.5%. In the same study, factors such as smoking, alcohol 65 
consumption, and cellular phone use had no correlation with the onset of cancer. A slight 66 
correlation was found in those that had suffered some cranial trauma years prior, however, the 67 
data was not statistically significant [6].   68 
Clinically, patients with a suspected glioma can manifest symptoms of headaches, 69 
seizures, numbness of the extremities, slurring or other problems with speech, vision loss, and 70 
raised intracranial pressure [7]. This is most likely due to mass effect in the brain secondary to 71 
the tumor size altering brain anatomy and physiology. Once a patient presents with any of these 72 
issues, a physician can make an accurate diagnosis with a neurological exam or imaging including 73 
magnetic resonance imaging (MRI) or computed tomography (CT). A biopsy involves the 74 
resection of a sample of the tumor to analyze the cells under a microscope [8]. Biopsy will 75 
determine if the tumor is benign or malignant and assist in the staging of the tumor and 76 
identification of causal cell lineage.  77 
Prognosis of gliomas is dependent on the grade and pathology of the tumor. Astrocytic 78 
tumors have the highest survivorship in Grades II to IV relative to other forms of glial cancers. For 79 
example, glioblastomas have 0.05% to 4.7% survival in the span of five years. However, a form of 80 
Grade I astrocytoma called pilocytic astrocytoma has a 94.4% survival rate in the same span [4]. 81 
Moreover, survival rates decrease significantly as age increases. Other factors that affect survival 82 
are the location of the tumor, the treatment administered, and genetic dispositions [9]. 83 
Treatment options are patient specific and depend on the severity of the presentation. 84 
Gliomas are very aggressive tumors and require intensive treatment to prolong life. Depending 85 
on the clinical scenario, a physician can utilize a multitude of therapeutic options including 86 
Cyberknife©, surgical excision, radiation, Gamma knife© or proton therapy to eradicate the 87 
tumor [1]. External beam radiotherapy or internal chemotherapy may be used as a primary or 88 
adjuvant therapy to improve the prognosis. Since 2004, targeted chemotherapy has continued 89 
to play an increasing role in the treatment of these cancers [10]. One of the main challenges is 90 
that even with utilizing the most advanced treatments available; patients can often experience 91 
tumor regrowth or significant iatrogenic neurological impairment. This ultimately challenges the 92 
patient's long-term prognosis, and impairs the quality of life. Post-therapeutic quality of life 93 
values remain of essential importance when discussing treatment options in patients with brain 94 
malignancies with a poor or limited prognosis, yet there are few resources available to guide such 95 
discussion. In this paper, we aim to compare and contrast two treatment approaches for gliomas: 96 
surgery and radiotherapy. We also attempt to address the central ethical considerations when 97 
deliberating the most appropriate therapeutic methods. Lastly, we aim to lay a foundational 98 
model to encourage patient-physician discourse of pertinent palliative and hospice-care topics 99 
to guide physicians and patient dialogue with regards to quality of life.   100 
2. Treatment Options for Cerebral Gliomas  101 
2.1 Surgical Interventions 102 
Surgical resection of gliomas has various advantages. Not only can an accurate diagnosis 103 
be made by direct biopsy of the tumor, but it also facilitates the use of adjuvant treatment 104 
options to prevent recurrence and prolong survival. Surgery usually begins with a craniotomy to 105 
access the brain. Patients are anaesthetized, intubated, and markers are placed before the head 106 
is shaved. Modern neurosurgical procedures are now implementing intraoperative imaging to 107 
more accurately resect tumors. Neuronavigation uses CT and/or MRI throughout surgery to 108 
assess any shifts in the position of the tumor. Neurosurgeons are able to see a three dimensional 109 
(3D) model of the tumor and change their surgical approach accordingly for the patient’s safety 110 
[11]. 5- Aminolevulinic acid is another method used by neurosurgeons to guide surgeries utilizing 111 
its fluorescence as a marker. Using violet-blue excitation light, neurosurgeons are able to detect 112 
the fluorescent margins of the tumor to assure safe resection [12]. Moreover, new and improved 113 
robotics such as the NeuroArm© can be even more precise than a human hand when incising the 114 
margins of a tumor, further decreasing the possibility of damage to the surrounding tissues, thus 115 
protecting against neurological deficits [13]. 116 
Surgery is often proposed to younger patients that have better ability to withstand 117 
possible postoperative complications. However, age is not the only factor surgeons consider to 118 
determine if surgery would be the safest and most efficacious treatment option. Factors such as 119 
tumor size and location also affect this determination. Larger tumors cannot be successfully 120 
treated by radiosurgery; therefore, surgery is most likely the better option for these patients. 121 
Similarly, tumors in close proximity to crucial areas of the brain are particularly dangerous and 122 
can ultimately result in major neurological deficits [14]. Surgery in this case is not recommended. 123 
Symptomatic patients are also ideal candidates for a surgical procedure [15]. 124 
As with any surgery, complications can be encountered during and after surgery. There is 125 
risk of intraoperative hemorrhage throughout the tumor resection. Post-surgical complications 126 
include neurological deficits including gross motor loss, seizures, unconsciousness, and 127 
dysphasia. Patients can also experience respiratory problems, arterial hypertension or 128 
hypotension, nausea, vomiting, headaches, and pain. Postoperative infections such as meningitis 129 
have been reported as well [15]. In a study conducted analyzing 22 patients, neurological deficits 130 
were found in 31.8% of patients after glioma resection. However, most recuperated by the time 131 
the patient was discharged [16]. 132 
Overall survival after resection is highly influenced by factors such as age and postsurgical 133 
complications. The median survival for a group of 1,229 patients treated at the University of 134 
Texas MD Anderson Cancer Center was 13.4 months. From this same population, patients that 135 
had 100% resection survived an average of 15.2 months while those that didn’t survived only 9.8 136 
months [17]. In addition, a study by the Department of Neurosurgery at the St. Olavs University 137 
Hospital reports that 47.5% of 144 patients treated at their facility survived one year post-138 
surgery. Only 16.0% survived to two years [18].  139 
2.2 Radiosurgery Interventions 140 
Unlike typical radiation treatments, radiosurgery minimizes the area exposed by targeting 141 
the tumor directly with the use of advanced computer programs and sophisticated technology. 142 
It can be delivered as one single treatment, stereotactic radiosurgery, or by fractions over a 143 
period of time, known as fractionated radiosurgery [19]. This is accomplished by emitting 144 
concentrated beams to the tumor, ultimately destroying the cancerous cells by damaging its DNA 145 
while protecting as many healthy cells possible. First developed in the mid-1950s, stereotactic 146 
radiosurgery has evolved into three forms of treatment which include Gamma Knife©, Linear 147 
Accelerator, and proton accelerator [20].   148 
Gamma Knife© radiosurgery requires the use of a head frame secured to the patient’s 149 
head with four pins. The center of the frame helps guide the beams to locate the tumor. The 150 
computer software, also known as Leksell Gamma Plan, has the imaging necessary from an MRI 151 
or CT scan to create a 3D blueprint of the tumor which eases the focus of beams within the head 152 
frame. Varying volumes of energy are delivered using the Gamma Knife depending on the size 153 
and position of the tumor [21]. 154 
All three modalities of radiosurgery follow almost the same procedure. The Linear 155 
Accelerator, also known as LINAC, focuses x-ray energy or electrons to the tumor much like the 156 
Gamma Knife. The LINAC system also used a head frame but has developed a frameless technique 157 
with the use of lasers to detect movement from the patient. This method has proven just as 158 
effective [22]. The proton accelerator uses a similar mechanism but instead uses protons to 159 
target the tumor. Before the procedure, patients are numbed at the four areas where the pins 160 
will be inserted. Once the head frame is installed, various scans will be used to pinpoint the 161 
location of the tumor. After the scans are analyzed by the software and a target plan has been 162 
executed, the patient lies down under the machine where their head frame is secured. As soon 163 
as the treatment is completed, the head frame is removed and the patient is observed for any 164 
adverse effects [23].   165 
Stereotactic radiosurgery (SRS) is a more prudent treatment option for those with tumors 166 
too small to be resected by a neurosurgeon. These tumors are typically less than 3.0 centimeters 167 
[24]. This less invasive procedure allows for the treatment of tumors in various parts of the body 168 
which include the brain, spine, liver, and even the abdominal cavity. Patients are conscious 169 
throughout the entire treatment and are allowed to resume all daily activities within two days. 170 
However, radiosurgery can be detrimental to the body. Patients can suffer from various side 171 
effects like nausea, vomiting, vertigo, and seizures [25]. It is also important to note that while 172 
radiation affects the DNA of the tumor it can also affect the healthy cells adjacent to it.  173 
The immobilization of the patient, even with a head frame or mask, is still a major source 174 
of complications in radiosurgery. The procedure relies on imaging to pinpoint the location of the 175 
tumor and any abrupt movement can force surgeons to start the planning process again. This 176 
proves to be quite difficult when treating children; therefore, sedation is used to minimize this 177 
issue. Patients with little to no bladder control and those with respiratory problems need to be 178 
assessed before treatment because these patients prove to be the most unstable. Even if the 179 
machines have an emergency stop option, frequent movement from these patients proves 180 
almost impossible to treat [26]. Further, a study conducted with patients diagnosed with high 181 
grade gliomas shows that 16% of the sample of 115 patients suffered from radiation necrosis. 182 
Necrosis is another complication of radiosurgery that occurs in nearly 30% of cases [27]. 183 
Despite the complications and various side effects, radiosurgery has proven very 184 
successful in prolonging survival in patients with cancer. In a population of 114 patients treated 185 
with SRS, the treatment achieved a survival period of 23 months instead of the 12 expected 186 
without treatment. However, in this study SRS was not as successful with grade 3 gliomas due to 187 
their larger size [28]. In yet another study with 106 patients treated with LINAC, the average 188 
survival was 15.5 months with 58% of patients surviving to one year and 28% to two. Local control 189 
was at 91% and 84% after the first and second year, respectively [22]. Outstanding local control 190 
was also encountered in patients who underwent Gamma Knife© radiosurgery. A 63 year old 191 
male was observed over a 7 year period as he underwent Gamma Knife radiosurgery for his 192 
recurrent glioma. For the first radiosurgery, the patient didn’t have a recurrence until after 4 193 
months. He repeated the radiosurgery for a second time and no recurrence was observed until 194 
after 14 months. The third and final repetition permitted another 69 months before he passed 195 
away [29]. Pairing radiosurgery with other treatment options is also feasible for patients and one 196 
that may be just as successful.  197 
3. Ethical Considerations in Determination of Treatment Approach 198 
One of the most essential ethical tenets in the practice of modern medicine is that of 199 
patient autonomy. This principle is of utmost importance in the determination of the necessity 200 
of risky, aggressive surgery. Ultimately, patients bare the power in the shared-decision making 201 
model. This is to say, consumers of healthcare are authorized to proceed with medical 202 
recommendations, ignore such advice, seek second opinions and manage their own care as they 203 
see fit. Patients, as the primary decision makers, receive a significant portion of clinical education 204 
from physicians, necessary in order to make the best health decisions for them. In the case of 205 
radical surgery, informed consent is the educational modality in which physicians may best 206 
enable patients to make such choices.  207 
Informed consent must play a critical role in developing patient understanding of the 208 
procedure, its risks and benefits. Any radical procedure mandates a more exhaustive consent 209 
than routine evaluation. Rather than merely completing the legally required documentation, 210 
physicians need to engage with patients in this preoperative period. The aggression of the 211 
consent process must match that of the operation. It is imperative that a more thorough model 212 
of informed consent be adopted in cases where the possibility of a positive outcome is less than 213 
certain. Meaning, patients must demonstrate understanding not only of the necessity of the 214 
procedure and mastery of what an operation entails, but rather exhibit comprehension of the 215 
risks, benefits and alternatives of the surgery presented. By expanding consent to include 216 
confirmation of appreciation of all of these aspects, whether by restating each element in the 217 
consent documentation or verbalizing each aspect in the pre-surgical consultation, the medical 218 
community may better prepare patients for radical surgery while ensuring their understanding 219 
of the likelihood of success, complications, quality of life after the surgery, morbidity and 220 
mortality. 221 
Ultimately, the perception of the physician as a savior of sorts may influence the decisions 222 
of patients to proceed with surgical intervention. Often patients in the most dismal states will 223 
value a physician who takes a risk with their treatment plan as a personal hero, which may not 224 
truly be of benefit. On the other hand, some physicians may promote risky procedures for 225 
financial gain in performing a procedure for conditions with a known poor prognosis regardless 226 
of therapy. Perhaps it is our efforts as providers rather than our treatment, necessarily, that 227 
dictates the perception of effort and aptitude of physicians by our patients. However, it is 228 
imperative that we do not take advantage of this relationship. As the principal source of medical 229 
counsel for patients, we must provide a breadth of options and truly comprehensive 230 
management to prevent patients from feeling limited in the options that exist for their treatment. 231 
An area grossly overlooked during these discussions include that of quality of life one can expect 232 
post-surgical/therapeutic treatment which is something patients often do not consider pre-233 
treatment. Undoubtedly, the ideation of a bright prognosis and a positive future is conducive for 234 
healing. In these cases, the physician’s primary role must be as the bearer of hope. 235 
3.1. Evaluating Quality of Life in the Context of Cerebral Gliomas 236 
Quality of life, though an explicitly individualized perception, is commonly evaluated using 237 
a fixed set of metrics. Among these are frustration in completing tasks, perception of decreased 238 
family contribution, fear of seizure, lack of independence, inability to drive, less enjoyment in 239 
leisure activities, decreased fulfillment from work, and inability to work to assess both brain-240 
specific and functional elements of quality of life [30]. Neurocognitive changes are generally 241 
expected in individuals with brain tumors. Changes in cognition that alter decision making 242 
capacity are common and may compromise the ability to consent to therapy or treatment, even 243 
after resection of the causal mass [31]. Beyond effects on management, this cognitive impact 244 
also affects the activities of daily living and independence [31]. In a study conducted by Kvale et 245 
al., that aimed to evaluate the quality of life in patients diagnosed with gliomas using the 246 
Functional Assessment of Cancer Therapy - Brain (FACT-Br); it was demonstrated that those with 247 
a glioma were assessed to experience a lower quality of life (mean 127.34± 21.29 St.Dev.) when 248 
compared to healthy individuals with a mean score of 86.5 [32, 33]. In this case, a higher the 249 
numerical value based upon the FACT-Br assessment corresponds with a reported lower quality 250 
of life. Such a lower score was attributed to a lack of functional independence and inability to 251 
contribute to family or work life. There was no statistically significant difference between 252 
demographic groups when evaluating quality of life. This assessment was similarity reported 253 
across all patients affected by gliomas, regardless of sex, color, class, or creed [32].  254 
3.2. Quality of Life Following Surgical Resection 255 
With advances in neurosurgical modalities, diffuse low-grade gliomas are mostly operable 256 
malignancies [34]. However, it is well supported that cognitive deficits are common following 257 
surgery for resection of brain masses [31]. In patients six week after surgery, new motor deficits, 258 
language deficits, ataxia, occipital lesions and lack of use of ultrasonography were all associated 259 
with decreased quality of life measured in a multivariate model of a neurocognitive battery [35]. 260 
As the field of neurosurgical oncology  continues to evolve with the advent of functional mapping, 261 
the quality of life for patients after surgery is an increasingly important outcome in the evolution 262 
towards “functional neurooncology” [34]. Neuropsychological evaluation as a routine element of 263 
care for those affected by gliomas may assist in both the evaluation of capacity and also aid in 264 
bolstering executive function in the days and weeks following surgery [31]. 265 
3.3. Quality of Life Following Radiotherapy 266 
It has been demonstrated that radiotherapy can cause damage to the white matter, 267 
resulting in cognitive impairment, apathy, motor control deficits, memory loss, and executive 268 
dysfunction [36]. Though non-specific to gliomas, treatment with radiation demonstrates a 269 
decline in neurocognitive performance, regardless of intensity of therapy [36]. However, some 270 
studies report that the use of whole brain radiation therapy (WBRT) demonstrates worse 271 
neurocognitive outcomes  than those treated with stereotactic radiosurgery alone (52% vs. 24% 272 
reporting immediate decline in verbal recall) [36]. However, between these two treatments, 273 
there was no statistically significant difference in quality of life based on the FACT-Br assessment 274 
of the psychosocial aspects of quality of life [36]. These findings are supported by other 275 
evaluations that show a larger difference in cognitive function versus quality of life following 276 
radiotherapy [37]. Despite these findings, it is argued that there are limitations in the instruments 277 
used to assess quality of life in patients affected by brain cancer [38]. Realistically, it is unlikely 278 
that any screening questionnaire will ever completely uncover the psychosocial elements that 279 
impact the lives of patients affected by glial cancers. Thus, continued neuropsychological support 280 
in clinic and at home must continue to evolve as an integral component of care for those affected 281 
by gliomas.  282 
4. Clinical Strategies 283 
4.1. Shared Decision Making 284 
When considering surgery, radiation or chemotherapy as a treatment option it is critical 285 
to evaluate the risk and benefits of each approach in a patient-centered manner. Further, the 286 
time commitment and possible adverse reactions or outcomes must be fully disclosed in order 287 
to best prepare patients to make the decisions that are best for them. This said, it is imperative 288 
to review the following factors essential in the shared decision making process as identified by 289 
Swetz, Kamal and Matlock [39]: 290 
 291 
1) The estimated prognosis - quality of life post-surgery vs. global life expectancy 292 
2) Current and anticipated best functional status outcome 293 
3) Expected toxicities or complications 294 
4) Treatment burden - time spent coming to treatment site, time off work for family, and 295 
cost.  296 
Shared decision making concedes power of medical choice to patients. Thus, the patients 297 
must be informed of their condition, proposed interventions, prognosis, alternatives, risks and 298 
benefits in order to fully shoulder this responsibility. When surveying data of patients with 299 
glioblastoma status post-surgical intervention, data showed that those with fewer unmet 300 
informational needs demonstrated a higher level of self-perceived quality of life [40]. Meaning, 301 
the more patients know about their condition, goals and prognosis, the more favorable the 302 
quality of life outcomes. However, other studies have demonstrated that further research is 303 
required in generating tools to assist in developing the shared decision making process, because 304 
patients with gliomas have demonstrated difficulties understanding the complexities of their 305 
conditions [41]. It has been shown that shortly after being diagnosed with a malignant glioma; 306 
many patients have an impaired capacity to make treatment decisions as compared to healthy 307 
patients [42]. More specifically, the impaired medical decision making capacity is directly related 308 
to short-term verbal memory deficits; hence, contributing to a potential lack of comprehension 309 
or acceptance of their medical condition. Additionally, it is most believed that the imposing 310 
gravity of the medical condition itself and its impact on the patients’ life and family further erodes 311 
mental cognition.   312 
4.2 Preparedness Planning  313 
Preparedness planning is considered practicing an integration of palliation with 314 
longitudinal care of seriously ill patients. This conversation can often begin with the process of 315 
advance care planning, the “ongoing process in which patients, their families, and their 316 
healthcare providers reflect on the patient’s goals, values, and beliefs, discuss how they should 317 
inform current and future medical care and ultimately use this information to accurately 318 
document the patient’s future health care” [43]. 319 
In the context of radical surgery, advance care planning assists families in working through 320 
all considerations-- success of treatment, quality of life, goals of care, concerns, and ethical 321 
qualms that may arise in the developmental process. These conversations must be complete and 322 
deliberate in order to protect loved ones from the burden of decision making during this 323 
immensely stressful time. Among the topics that must be addressed are complications, functional 324 
status postoperatively, progression of disease, and deterioration of quality of life amongst others 325 
[43]. 326 
Often, these discussions are inadequate. Though no advance directive can possibly be 327 
comprehensive enough to cover all possible scenarios, recent focus driven by insurance 328 
mandates in primary care have focused on life-saving interventions rather than on health status. 329 
Far too often these conversations happen in emergency circumstances. Seldom are the risks and 330 
benefits of surgery discussed, nor are the options of other interventions or the possibility of 331 
forgoing treatment. The approach is far too often the suggestion of only one treatment option 332 
and discussing it in a favorable lens without acknowledging the efficacy of other modalities. 333 
Ultimately, it is a sophisticated understanding of a patient’s wishes that is the most effective, 334 
ethical approach for clinicians and families to honor patients. Incorporation of advance care 335 
planning into daily practice is critical in allowing for improved care and interventions throughout 336 
life that are in accordance with a patient’s desires, with respect to their autonomy and dignity.  337 
In the context of cerebral gliomas, it is vital to use advance care planning into patient care 338 
plans throughout the course of the disease. Involving palliation early in the progression of disease 339 
permits care teams can assist in shared decision making and advance care planning. 340 
Understanding the natural history of disease and early definitions of care goals through effective, 341 
family-centered communication allows physicians to address barriers in palliative care to 342 
improve the quality of life and to allow for death with dignity.  343 
When discussing goals of care, it is important for physicians to not only understand, but 344 
appreciate the importance of the subjective meaning of ‘quality of life’. Examples of such 345 
variability includes being able to watch a baseball on television, being with their family; while 346 
others might feel a ‘quality of life’ is being able to climb mount Everest or  flying a plane. Eric 347 
Cassell defines suffering as a state of severe distress associated with events that threaten the 348 
intactness of personhood or the interconnected physical, social, spiritual, and psychological 349 
aspects of self [44]. 350 
Physicians tend to focus on the simplest controllable component of suffering - physical 351 
distress. However, alleviating suffering not only devalues the important components of 352 
personhood, but it also causes loss of empathetic communication skills with the patient, and 353 
places a focus on the human body rather than the whole person which includes many other 354 
subjective components such emotion, spiritualism, and psyche amongst others. A physician’s job 355 
is to treat the person’s well-being, not limited to the objective disease. Treating the subjective 356 
well-being is about the caring for the reasons one wishes to be alive.  357 
5. Conclusion 358 
Credited to the ethos of conventional Western medicine, there is a profound attention to 359 
extension of life which would otherwise be shortened without medical intervention. As such, 360 
there is often an oversight of extension of life with minor reflections on quality. However, this 361 
can be emotionally difficult for the patient, their family and the physician/medical care team 362 
alike. There is a growing need to refocus on the quality and well-being of a patient’s life 363 
undergoing radical therapy for conditions like glial cancer, rather than merely extending life with 364 
a poor quality by exploring the central juxtaposition of living vs. existing. This is especially true 365 
for patients with brain neoplasms refractory to conventional therapeutic management such as 366 
radiation and surgical interventions. In these cases, a care-planning dialogue between the 367 
physician with patients and families can be emotionally challenging for both physicians and 368 
families. To focus on a more holistic discourse, we have provided a framework that outlines 369 
several points of discussion for guiding a family-centered conversation to focus on quality of life 370 
and its interconnected physical, social, spiritual and psychological aspects.  371 
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